Literature DB >> 2646620

Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation.

P M Plezia1, T H Kramer, J Linford, S R Hameroff.   

Abstract

A new transdermal drug-delivery system that administers the synthetic opioid fentanyl through intact skin was evaluated for 24 hours postoperatively in eight patients who had undergone orthopedic surgery. Plasma samples were obtained over a 72-hour period for pharmacokinetic analysis in five patients. The patients were also evaluated intensively for adequacy of analgesia, frequency of nausea and sedation, and occurrence of ventilatory depression. A median lag time of 2.25 hours after application of the transdermal system was observed before the appearance of fentanyl in the blood. Median peak concentration and time to peak were 1.0 ng/ml and 22 hours, respectively. The apparent elimination of fentanyl after transdermal administration is prolonged relative to previously reported values. Absorption analysis indicates zero-order fentanyl administration, and in addition, suggests deposition of drug in an epidermal site, with the resultant prolonged absorption process giving the appearance of slow elimination. No significant toxicities were observed. Four patients required no additional analgesia. No consistent correlations among fentanyl concentration and any clinical values were observed. Transdermal administration of fentanyl appears to be a viable alternative to conventional routes of narcotic administration and warrants further study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646620     DOI: 10.1002/j.1875-9114.1989.tb04096.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  Pharmacotherapy of opioids: present and future developments.

Authors:  T F Meert
Journal:  Pharm World Sci       Date:  1996-01

Review 3.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Day-to-day titration of transdermal fentanyl is unwise.

Authors:  D Brooks
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

Review 5.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

6.  [Transdermal fentanyl for the treatment of cancer pain.].

Authors:  B Donner; M Zenz; M Tryba; M Strumpf
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

Review 7.  Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.

Authors:  Craig A Kornick; Juan Santiago-Palma; Natalia Moryl; Richard Payne; Eugenie A M T Obbens
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Formulations of fentanyl for the management of pain.

Authors:  Sina Grape; Stephan A Schug; Stefan Lauer; Barbara S Schug
Journal:  Drugs       Date:  2010       Impact factor: 9.546

9.  Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.

Authors:  Evelien J M Kuip; Wendy H Oldenmenger; Martine F Visser-Thijs; Peter de Bruijn; Esther Oomen-de Hoop; Ron H J Mathijssen; Carin C D Van der Rijt; Stijn W Koolen
Journal:  Oncotarget       Date:  2018-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.